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Abstract
Introduction Atrial high-rate episodes (AHREs) are associated with an increased risk of developing atrial fibrillation and 
thromboembolism. The characteristics of ‘real world’ patients developing AHREs are poorly known.
Methods We included 496 consecutive patients with cardiac implantable electronic devices (CIEDs). Primary endpoint 
was occurrence of AHREs, defined as > 175 bpm and lasting > 5 min, in a median follow-up of 16.5 (IQR 3.9–38.6) months 
(1082.4 patient-years). We also tested the predictive value of clinical risk scores for AHREs.
Results Mean age was 68.8 ± 14.0 years, and 35.5% were women; AHREs were recorded in 173 patients [34.7%, 16.0%/year, 
95% confidence interval (CI) 13.7–18.6]. Multivariable Cox regression analysis showed that age [hazard ratio (HR) 1.020, 
95% CI 1.004–1.035, p = 0.011], prior AF (HR 3.521, 95% CI 2.831–5.206, p < 0.001), white cell count (HR 1.039, 95% CI 
1.007–1.072, p = 0.016) and high C reactive protein (CRP; HR 1.039, 95% CI 1.021–2.056, p = 0.038) were independently 
associated with AHREs. ROC curve analysis showed that the APPLE score (C statistic 0.53, 95% CI 0.48–0.59; p = 0.296) 
ALARMEc score (C statistic 0.51, 95% CI 0.44–0.57; p = 0.810) were non-significantly associated with AHRE. Similar 
results were obtained for  CHADS2 and  CHA2DS2VASc score
Conclusion AHREs are common in CIEDs patients, with age, prior AF, inflammatory markers (high CRP, white cell count) 
being factors associated with AHREs onset. Clinical risk scores showed limited value for AHREs prediction in this cohort.
Keywords AHREs · Implantable device · Pacemaker · Atrial fibrillation · Inflammation
Introduction
Previous studies showed that atrial high-rate episodes 
(AHREs) are associated with an increased risk of new-
onset atrial fibrillation (AF) [1], thromboembolism [2–4] 
and cardiovascular mortality [5]. Subclinical ischaemic brain 
lesions have also been described in patients with AHREs [6]. 
However, the thromboembolic risk of AHRE may be lower 
when compared to patients with AF, and a significant pro-
portion of ischemic strokes recorded in patients with AHREs 
do not show a significant temporal relationship with AHREs 
occurrence [7].
Although implicated to play role in cryptogenic stroke, 
the clinical significance of AHREs is not well understood 
and the management of these patients is not evidence-based. 
Furthermore, clinical characteristics and risk factors associ-
ated with the development of AHREs are poorly described.
Conventional diagnostic methods, such as resting ECG 
and Holter monitoring have limited value in the detection 
of paroxysmal AF and AHREs [8]. Conversely, current use 
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of cardiac implanted electronic devices (CIEDs), includ-
ing pacemakers and implantable defibrillators lead to an 
improvement in the early detection of atrial and ventricular 
arrhythmic episodes, especially in patients that are asymp-
tomatic [9]. AHREs lasting > 5 min are considered as clini-
cally relevant, and patients presenting with AHREs should 
be assessed for the presence of other risk factors for stroke, 
and regularly screened to detect overt AF to consider of 
antithrombotic therapy [10].
We investigated incidence and factors associated with the 
development of AHREs in a cohort of consecutive patients 
who underwent CIEDs implantation.
Methods
We included all consecutive patients with CIEDs includ-
ing DDD pacemaker, implantable cardioverter defibrillator 
(ICD), or cardiac resynchronization therapy (CRT) device, 
who attended the Cardiology Department of Sandwell and 
West Birmingham Hospitals NHS Trust (Sandwell General 
Hospital and City Hospital) in Birmingham, United King-
dom from December 2010 to August 2017. We excluded 
patients with single-chamber VVI devices and patients with 
< 3 months of follow-up. The atrial sensitivity was pro-
grammed to 0.5 mV with bipolar sensing.
At baseline, personal medical history and information on 
co-morbidities and concomitant medications were collected. 
The primary endpoint for the study was the occurrence of 
AHRE, defined as > 175 bpm and lasting > 5 min. Baseline 
clinical characteristics of patients with and without AHREs 
were compared. This study was conducted in accordance 
with the EU Guidance on Good Clinical Practice CPMP/
ECH/135/95 and the Declaration of Helsinki.
Clinical risk scores
We tested the predictive value of clinical risk scores in pre-
dicting the occurrence of AHREs. The various scores were 
calculated as follows:
 (i) APPLE score: Age [> 65 years (A), persistent AF 
(P), impaired eGFR (< 60 ml/min/1.73 m2) (P), LA 
diameter ≥ 43 mm (L), and EF < 50% (E). Each vari-
able scored 1 point with the score ranging from 0 to 
5 points;
 (ii) ALARMEc score: AF type (A), Left Atrial size [nor-
malized left atrial area (NLA) ≥ 10.25], Renal insuf-
ficiency (eGRF < 68 ml/min), Metabolic syndrome 
and cardiomyopathy (c) with each variable scoring 
1 point, and the score values ranging from 0 to 5 
points. The ALARMEc score was calculated in a 
subgroup of 250 patients with complete information 
on metabolic syndrome. For APPLE and ALARMEc 
scores left atrial enlargement was calculated as a nor-
malized left atrial volume/body surface area > 28 ml/
m2.
 (iii) CHADS2 score: congestive heart failure, hyperten-
sion, age ≥ 75, diabetes mellitus, prior stroke or TIA. 
Each variable was assigned 1 point, prior stroke or 
TIA was scored 2 points, ranging from 0 to 6 points;
 (iv) CHA2DS2-VASc score: congestive heart failure, 
hypertension, age ≥ 75, diabetes mellitus, prior 
stroke or transient ischemic attack, vascular disease, 
age 65 to 74, female; 2 points assigned to age ≥ 75 
and prior stroke or TIA; 1 point to every other vari-
able, ranging from 0 to 9 points.
Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation (SD) or median and interquartile range (IQR), as 
appropriate. Categorical variables were expressed as num-
bers and percentages. The Pearson χ2 test was used to com-
pare proportions.
Cox proportional hazards analyses were used to calculate 
the adjusted relative hazard ratio (HR) by each clinical vari-
able. In the multivariable Cox regression model, only vari-
ables with a p < 0.100 at univariate analysis were entered. 
Statistical significance was set at a p value < 0.05.
We also tested the predictive value of clinical risk scores 
such as APPLE, ALARMEc,  CHADS2 and  CHA2DS2VASc 
score. To investigate the predictive performance (expressed 
as c-indexes) of these scores, we used receiver operat-
ing characteristic (ROC) curves, and compared them as 
described by DeLong et al. [11]. All tests were two-tailed 
and analyses were performed using computer software 
packages (IBM SPSS 23.0 for  Windows®, SPSS Inc.) and 
 MedCalc® V. 18.4.1.
Results
We included 496 consecutive patients undergoing CIEDs in 
this study. Indications for CIEDs implantation included sick 
sinus syndrome (22.2%), heart block (34.9%), heart failure 
(26.3%), ventricular tachycardia/fibrillation (13.0%), other 
(2.8%, e.g., recurrent/malignant vasovagal syncope, sympto-
matic bradycardia), and unknown (0.8%, 4 patients).
Mean age was 68.8 ± 14.0 years, and 35.5% were women. 
Table 1 reports baseline characteristics of patients with and 
without AHREs. Patients with detected AHREs were older, 
with a higher prevalence of prior AF (and accordingly, 
higher use of oral anticoagulants), digoxin use, higher bili-
rubin and white cell count (Table 1).
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Predictors of AHREs
28 patients with missing data at follow-up were excluded 
from this analysis. Hence, 471 CIEDs patients were included 
in the Cox regression model. Overall, 173 AHREs (34.7%) 
were recorded during a median follow-up of 16.5 (IQR 
3.9–38.6) months yielding 1082.4 patient-years of observa-
tion (incidence rate 16.0%/year, 95% CI 13.7–18.6).
Based on results from univariate Cox regression analy-
sis (Table 2), age, atrial fibrillation, stroke/TIA, white cell 
count, bilirubin, diuretic, antiplatelet, and digoxin were 
used as covariates in the multivariable model. The variable 
“oral anticoagulation” was excluded from the final model as 
> 90% of these patients were already classified as “having 
AF”. However, in a fully adjusted model “oral anticoagula-
tion” was not significant, and this exclusion did not modify 
final results (data not shown). The multivariable Cox regres-
sion analysis showed that age [hazard ratio (HR) 1.020, 95% 
CI 1.004–1.035, p = 0.011], prior AF (HR 3.521, 95% CI 
2.831–5.206, p < 0.001), white cell count (HR 1.039, 95% CI 
1.007–1.072, p = 0.016) and high CRP (above median, HR 
1.039, 95% CI 1.021–2.056, p = 0.038) were independently 
associated with AHREs onset (Table 2).
Clinical risk scores for AHREs
Clinical risk scores showed only modest and statistically 
non-significant predictive ability for AHREs. ROC curves 
for each score are shown in supplementary Fig. 1. The 
APPLE Score was tested on 348 patients with 132 AHREs, 
and had a C statistic of 0.53 (95% CI 0.48–0.59) p = 0.296. 
The ALARMEc score was tested on 233 patients with 93 
incident AHREs and a C statistic of 0.51 (95% CI 0.44–0.57) 
p = 0.810. In this subgroup where metabolic syndrome could 
be defined, the C statistics for the APPLE score was 0.56, 
95% CI 0.50–0.63; p = 0.054. Similar non-significant results 
were obtained for  CHADS2 and  CHA2DS2  VASc2 scores 
(see supplementary Fig. 1).
Discussion
The main findings of this ‘real world’ cohort study are as 
follows: (1) more than 30% of CIEDs recipients have device-
detected AHREs, (2) presence of AF, older age, high CRP 
and white cell count all independently predicted incident 
AHREs, and (3) clinical risk scores have generally limited 
value for AHREs prediction.
The reported incidence of AHRE in previous studies 
ranges from 30 to 70% according to different definitions 
used [2]. Some studies defined AHRE by a rate between 
170 and 225 bpm, with the duration of the episode > 20 s 
or > 5–6 min [12]. In our cohort, 34.6% of patients had a 
Table 1  Baseline characteristics of patients according to AHREs 
occurrence
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin 
receptor blocker, AF atrial fibrillation, ALT alanine aminotransferase, 
CAD coronary artery disease (previous myocardial infarction, cardiac 
revascularization), CRP C reactive protein, eGFR estimated glomeru-
lar filtration rate, LA left atrium, TIA transient ischaemic attack
AHRE (≥ 5 min) p value
No (n = 323) Yes (n = 173)
Women (%) 37.5 31.8 0.238
Age (years) 67.9 ± 14.4 70.3 ± 13.2 0.078
AF (any type) (%) 9.8 39.5 < 0.001
 Paroxysmal AF (%) 6.4 26.9
 Persistent AF (%) 0.6 5.3
 Permanent AF (%) 2.6 7.6
Hypertension (%) 66.8 65.3 0.763
Diabetes (%) 30.1 29.1 0.837
Heart Failure (%) 40.8 37.4 0.498
CAD (%) 41.6 36.8 0.333
Stroke/TIA (%) 9.2 12.8 0.219
Metabolic syndrome 
(n = 250, %)
46.6 41.2 0.438
Waist circumference 
(n = 250, cm)
104.3 ± 14.7 102.5 ± 14.8 0.335
LA enlargement (n = 348, %) 57.4 62.9 0.368
Ejection fraction (n = 358, 
%)
45.4 ± 18.6 48.4 ± 16.8 0.119
Haemoglobin (g/l) 132.3 ± 18.4 133.3 ± 18.3 0.573
Platelet count (× 109/l) 241.8 ± 76.6 229.1 ± 63.6 0.064
White cell count (× 109/l) 7.8 ± 2.4 8.7 ± 5.7 0.011
CRP (mg/l) 3.0 (2.0–10) 5.0 (2.5–11.5) 0.150
High CRP (above median) 
(%)
47.9 56.6 0.099
Creatinine (μmol/l) 100.4 ± 55.0 99.2 ± 42.7 0.797
eGFR classes 0.480
 > 90 ml/min/1.7 18.9 16.2
 89–50 ml/min/1.7 50.9 50.3
 49–30 ml/min/1.7 25.5 30.6
 < 30 ml/min/1.7 4.7 2.9
eGFR < 68 ml/min/1.7 (%) 47.5 50.3 0.572
eGFR < 60 ml/min/1.7 (%) 30.2 33.5 0.477
ALT (U/l) 28.2 ± 25.9 29.0 ± 32.0 0.786
Potassium (mmol/l) 4.6 ± 2.4 4.5 ± 0.5 0.460
Bilirubin (μmol/l) 11.7 ± 6.8 13.0 ± 9.9 0.048
Beta Blockers (%) 40.2 42.4 0.699
ACEI/ARB (%) 57.0 57.6 0.924
Diuretic (%) 43.4 50.0 0.181
Oral anticoagulant (%) 13.0 36.8 < 0.001
Antiplatelet (%) 49.4 40.4 0.058
Digoxin (%) 3.8 11.8 0.002
Amiodarone (%) 8.9 9.4 0.869
Statin (%) 63.0 62.4 0.922
Calcium channel blocker (%) 19.9 18.2 0.718
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detected AHRE, with an incidence rate of 16.0%/year. This 
percentage is similar to that observed in the ASSERT study, 
which included 2580 patients with CIEDs and no history 
of AF, and demonstrated that the AHREs lasting more than 
6 min were found in 34.7% of the patients over a mean fol-
low-up of 2.5 years [1].
We found that increasing age, AF, high CRP and white 
blood cell count were all independently associated with 
AHRE occurrence. While age and the presence of supraven-
tricular arrhythmia, such as AF, have been already described 
as predictors of AHRE/AF, we—as far as we are aware—are 
the first to describe association between increased inflam-
matory markers and incidence of AHREs with a direct asso-
ciation between peri-implantation inflammatory biomarkers 
(CRP and white cell count) and incidence of AHREs during 
follow-up.
Similarly, a previous study has shown that high post-
cardiac surgery white cell count was associated with 
an increased risk of post-operative AF [13]. This find-
ing reinforces the association between inflammation and 
the occurrence/recurrence of atrial arrhythmia and may 
represent a common pathogenetic pathway linking AHREs 
to AF [14]. Thus, upon activation, white cells produce a 
number of inflammatory mediators, such as cytokines and 
reactive oxidant species, which interact with cardiomyo-
cytes of atrial tissue leading to electrical remodelling and 
fibrosis development [15]. The presence of AHREs may 
represent an early manifestation of this (pro-inflammatory) 
process.
Moreover, inflammatory mediators favour to a pro-throm-
botic state [16, 17], which may account for the increased risk 
of thromboembolism and cardiovascular mortality also in 
this setting. Hence, the relationship between inflammation 
and cardiovascular events in patients with AHREs deserves 
further research.
Interestingly, we found no significant association between 
anti-arrhythmic drugs, such as amiodarone, beta blockers 
or digoxin, and AHRE incidence. This result suggests that 
the optimal management of patients with AHREs is still to 
find, and further research is needed to optimize anti-arrhyth-
mic therapy to minimize the burden of silent arrhythmic 
episodes.
Table 2  Cox regression analysis 
for AHREs predictors
See Table 1 for abbreviations
Univariate Multivariate
Hazard ratio 95% confi-
dence interval
p value Hazard ratio 95% confi-
dence interval
p value
Age 1.023 1.011 1.035 < 0.001 1.020 1.004 1.035 0.011
Female sex 0.860 0.620 1.194 0.369
Atrial fibrillation 4.877 3.556 6.690 < 0.001 3.521 2.831 5.206 < 0.001
Hypertension 1.101 0.795 1.523 0.563
Diabetes 1.104 0.790 1.542 0.562
Heart failure 0.904 0.659 1.241 0.533
Stroke/TIA 1.507 0.959 2.369 0.075 1.458 0.902 2.355 0.124
Coronary artery disease 0.885 0.645 1.215 0.450
Haemoglobin 0.994 0.985 1.002 0.153
Platelet count 0.999 0.996 1.001 0.276
White cell count 1.048 1.021 1.077 0.001 1.039 1.007 1.072 0.016
High CRP 1.547 1.108 2.159 0.010 1.449 1.021 2.056 0.038
Creatinine 1.000 0.996 1.004 0.932
ALT 0.998 0.991 1.006 0.674
Potassium 0.924 0.748 1.140 0.461
Bilirubin 1.022 1.002 1.042 0.031 1.006 0.986 1.027 0.572
Beta blockers 1.016 0.744 1.386 0.922
ACEI/ARB 1.029 0.753 1.406 0.858
Diuretic 1.308 0.963 1.778 0.086 0.887 0.619 1.271 0.514
Oral anticoagulation 3.855 2.803 5.302 < 0.001
Antiplatelet 0.688 0.504 0.940 0.019 0.783 0.539 1.137 0.199
Digoxin 2.217 1.388 3.541 0.001 1.357 0.791 2.330 0.268
Amiodarone 0.912 0.543 1.532 0.727
Statin 1.019 0.741 1.402 0.906
Calcium channel blockers 1.173 0.793 1.737 0.424
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Several clinical risk scores have been proposed to predict 
new-onset atrial tachyarrhythmias [18]. However, most were 
done on small cohorts and had no certain external valida-
tion. In our cohort, we tested two of these scores, namely 
the APPLE and ALARMEc scores, and our results suggest 
that both have limited predictive value.
The coexistence of prior AF in up to 40% of patients 
developing AHRE indicates the close link between the two 
conditions, representing the clinical continuum of atrial 
tachyarrhythmias. This may support the need for stroke pre-
vention in patients with AHREs which is currently under 
evaluation in randomized control trials; two ongoing trials 
are exploring this issue [19, 20]. Apart from CIEDs, increas-
ingly sophisticated means of monitoring (e.g., implanted 
loop recorders) to detect AHREs in various clinical settings 
and high-risk groups, that would merit consideration of 
stroke prevention, have been recently investigated [21–23]. 
Of note, a recent consensus document from the European 
Heart Rhythm Association recommended that patients 
presenting with subclinical atrial tachyarrhythmias (i.e., 
AHRE > 5 min) should be considered for oral anticoagula-
tion when ≥ 2 stroke risk factors using the  CHA2DS2-VASc 
score are present [24].
Limitations
The study has some limitations. This was a single-centre 
study performed in hospital-based setting. As the atrial 
amplitude during AF decreases, the incidence of AHRE may 
be underestimated, leading to missed AHRE or to separate a 
long AHRE episode into multiple brief episodes. Addition-
ally, we did not store all electrogram of AHREs, but device 
diagnostic information on AHREs was reviewed by at least 
one experienced electrophysiologist whether they were true 
AHREs or other device-oversensing events, blinded to clini-
cal outcomes.
In conclusion, AHREs are common in CIEDs patients, 
with age, prior AF and inflammatory indexes (high CRP, 
white cell count) being factors associated with AHREs 
onset. Clinical risk scores showed limited value for AHREs 
prediction in this cohort.
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